GlassScriptPhysician profile
Kristine Roy
NPI 1255825782
$776.93
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $579 · 2023: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $198.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.37 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $112.17 | 2022-2023 | |
| Novo Nordisk INC | $94.17 | 2022-2023 | Rybelsus, Ozempic |
| Lilly USA, LLC | $75.23 | 2022-2023 | Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $45.75 | 2022-2023 | Farxiga |
| Abbvie INC. | $44.52 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.01 | 2022 | |
| Pfizer INC. | $37.55 | 2023 | |
| Merck Sharp & Dohme LLC | $33.33 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $30.95 | 2022 | |
| Amarin Pharma, INC. | $21.43 | 2022 | |
| Sunovion Pharmaceuticals INC. | $20.61 | 2022 | |
| Abbott Laboratories | $20.27 | 2022 | |
| Antares Pharma, INC. | $17.82 | 2022 | |
| Amgen INC. | $17.73 | 2023 | Otezla, Repatha |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $17.50 | 2023 | Loreev Xr, Gralise, Sertraline Hcl |
| Nestle Healthcare Nutrition INC. | $12.67 | 2022 | |
| Glaxosmithkline, LLC. | $11.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristine Roy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.